[1] Leonard DGB. Molecular Pathology in Clinical Practice[M]. New York:Springer Science+Business Media, 2007:15-40.

[2] Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia:an emerging transdisciplinary and interdisciplinary field[J]. Gut, 2011, 60(3): 397-411.

[3] Busam KJ, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions[J]. Am J Surg Pathol, 2013, 37(3): 413-420.

[4] Rubenstein JH, Enns R, Heidelbaugh J, et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome[J]. Gastroenterology, 2015, 149(3): 777-782.

[5] Jin M, Hampel H, Zhou X, et al. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome[J]. Am J Clin Pathol, 2013, 140(2): 177-183.

[6] Valentini AM, Pirrelli M, Caruso ML. EGFR-targeted therapy in colorectal cancer:does immunohistochemistry deserve a role in predicting the response to cetuximab?[J]. Curr Opin Mol Ther, 2008, 10(2): 124-131.

[7] Desai AN, Jere A. Next-generation sequencing:ready for the clinics?[J]. Clin Genet, 2012, 81(6): 503-510.

[8] Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry[J]. J Mol Diagn, 2008, 10(4): 293-300.

[9] Bosman FT, Carneiro F, Hruban RH, et al. World Health Organization Tumours. WHO Classification of Tumours of the Digestive System[M]. Lyon:IARC Press, 2010:134-177.

[10] Ruzzo A, Graziano F, Canestrari E, et al. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients[J]. Curr Cancer Drug Targets, 2010, 10(1): 68-79.

[11] Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy:American Society of Clinical Oncology Provisional Clinical Opinion Update 2015[J]. J Clin Oncol, 2016, 34(2): 179-185.

[12] Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J]. Cancer Res, 2006, 66(8): 3992-3995.

[13] De Mattos-Arruda L, Dienstmann R, Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer[J]. Clin Colorectal Cancer, 2011, 10(4): 279-289.

[14] Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2010, 9(5): 274-281.

[15] Feller JK, Yang S, Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma[J]. Mod Pathol, 2013, 26(3): 414-420.

[16] Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma[J]. Am J Surg Pathol, 2013, 37(1): 61-65.

[17] Chen Q, Xia C, Deng Y, et al. Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients[J]. Tumour Biol, 2014, 35(6): 5727-5733.

[18] Corcoran RB, Ebi H, TurkeAB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib[J]. Cancer Discov, 2012, 2(3): 227-235.

[19] Niessen RC, Berends MJ, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer[J]. Gut, 2006, 55(12): 1781-1788.

[20] Christensen M, Katballe N, Wikman F, et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing[J]. Cancer, 2002, 95(11): 2422-2430.

[21] Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy:a meta-analysis of colorectal cancer survival data[J]. Eur J Cancer, 2010, 46(15): 2788-2798.

[22] Webber EM, Kauffman TL, O'Connor E, et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy[J]. BMC Cancer, 2015, 15:156.

[23] 彭俊玲，汤涛，叶祖禄，等. 散发性结直肠癌微卫星不稳定状态与错配修复蛋白表达缺失及临床病理特征的相关性[J]. 中国肿瘤生物治疗杂志，2015，22（4）：479-483.

[24] Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology Features in Bethesda Guidelines Predict Colorectal Cancer Microsatellite Instability:A Population-Based Study[J]. Gastroenterology, 2007, 133(1): 48-56.

[25] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.

[26] Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome[J]. Am J Surg Pathol, 2013, 37(10): 1592-1602.

[27] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis[J]. Cell, 1990, 61(5): 759-767.

[28] Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development[J]. N Engl J Med, 1988, 319(9): 525-532.

[29] Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers[J]. Nature, 1997, 386(6625): 623-627.

[30] Pino MS, Chung DC. The chromosomal instability pathway in colon cancer[J]. Gastroenterology, 2010, 138(6): 2059-2072.

[31] Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer [J]. Proc Natl Acad Sci U S A, 1999, 96(15): 8681-8686.

[32] Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features [J]. Histopathology, 2007, 50(1): 113-130.

[33] The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2013, 487(7407): 330-337.

[34] Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy[J]. Nat Med, 2013, 19(5): 619-625.

[35] Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer[J]. J Pathol, 2013, 231(1): 63-76.

[36] Slattery ML, Herrick JS, Pellatt DF, et al. MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa:variations in miRNA expression and disease progression[J]. Carcinogenesis, 2016, 37(3): 245-261.

[37] Han D, Wang M, Ma N, et al. Long noncoding RNAs:novel players in colorectal cancer[J]. Cancer Lett, 2015, 361(1): 13-21.